Generation of B-cell-based cellular vaccine for cancer in murine models

David Hou; Joshua L Katz; Catalina Lee-Chang

doi:10.1016/j.xpro.2023.102219

Generation of B-cell-based cellular vaccine for cancer in murine models

STAR Protoc. 2023 Apr 20;4(2):102219. doi: 10.1016/j.xpro.2023.102219. Online ahead of print.

Authors

David Hou¹, Joshua L Katz¹, Catalina Lee-Chang²

Affiliations

¹ Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Lou and Jean Malnati Brain Tumor Institute, Chicago, IL, USA.
² Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Lou and Jean Malnati Brain Tumor Institute, Chicago, IL, USA. Electronic address: catalina.leechang@northwestern.edu.

Abstract

A B-cell-based cellular vaccine (B_Vax), produced from 4-1BBL⁺ B cells, can select tumor-specific B cells that, upon ex vivo culture, can generate tumor-specific antibodies and activate T cells. Here, we present a protocol to generate a B-cell-based vaccine in a CT2A orthotopic glioma murine model. We describe steps for B_Vax production involving glioma cell implantation, tissue harvesting, 4-1BBL⁺ B cell isolation, and activation. We also describe assessing B_Vax phenotype in vitro and in vivo functional status. For complete details on the use and execution of this protocol, please refer to Lee-Chang et al. (2021).¹.

Keywords: Cancer; Immunology.

Grants and funding

R37 CA258426/CA/NCI NIH HHS/United States